COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

COLO.B.DK

569.6

-0.14%↓

GMAB.DK

2,089

+3.06%↑

HLUNB.DK

45.28

+1.8%↑

ZEAL.DK

512.6

+1.75%↑

AMBUB.DK

107.1

+3.38%↑

Search

Novo Nordisk A-S (Class B)

Suletud

379 2.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

366.1

Max

382

Põhinäitajad

By Trading Economics

Sissetulek

-2.5B

27B

Müük

-1.2B

77B

P/E

Sektori keskmine

13.758

35.739

Aktsiakasum

5.96

Dividenditootlus

3.31

Kasumimarginaal

34.484

Töötajad

78,387

EBITDA

44B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.53% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.31%

3.08%

Järgmine tulemuste avaldamine

5. nov 2025

Turustatistika

By TradingEconomics

Turukapital

141B

1.5T

Eelmine avamishind

376.94

Eelmine sulgemishind

379

Novo Nordisk A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. okt 2025, 08:54 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18. aug 2025, 13:52 UTC

Suurimad hinnamuutused turgudel

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6. aug 2025, 06:52 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6. aug 2025, 06:21 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

1. okt 2025, 09:05 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29. sept 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22. sept 2025, 13:43 UTC

Omandamised, ülevõtmised, äriostud

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18. sept 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18. sept 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18. sept 2025, 08:55 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11. sept 2025, 10:59 UTC

Market Talk

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10. sept 2025, 13:24 UTC

Tulu

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10. sept 2025, 09:16 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2. sept 2025, 09:14 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21. aug 2025, 08:49 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18. aug 2025, 09:23 UTC

Kuumad aktsiad

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8. aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. aug 2025, 11:32 UTC

Tulu

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 11:03 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 10:41 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6. aug 2025, 20:34 UTC

Tulu

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6. aug 2025, 08:45 UTC

Tulu

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6. aug 2025, 07:19 UTC

Market Talk
Tulu

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6. aug 2025, 05:50 UTC

Tulu

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6. aug 2025, 05:48 UTC

Tulu

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6. aug 2025, 05:46 UTC

Tulu

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6. aug 2025, 05:38 UTC

Tulu

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6. aug 2025, 05:37 UTC

Tulu

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S (Class B) Prognoos

Hinnasiht

By TipRanks

9.53% tõus

12 kuu keskmine prognoos

Keskmine 1,162.73 DKK  9.53%

Kõrge 1,550 DKK

Madal 720 DKK

Põhineb 11 Wall Streeti analüütiku instrumendi Novo Nordisk A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

7

Osta

2

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat